



## FRIDAY 14<sup>TH</sup> NOVEMBER

TIME	EVENT	SPEAKER
815	REGISTRATION	
900	Welcome to country & Welcome Address	Dr Grant McArthur, AO Dr Sandro Porceddu Dr Shankar Siva
	SESSION 1	
910	Are patients preferring SABR over surgery for early- stage lung cancer?	Dr Drew Moghanaki
950	Celiac plexus SABR	Dr Lauren Henke
1030	Break SESSION 2	
1100	How to treat poly-metastatic disease with SABR - Lessons from the ARREST trial	Dr Melissa O'Neil
	Interactive session #1:	Facilitators:
1140	How to select a patient with oligoprogression for SABR	Dr Steven David & Dr Mark Shaw
1240	Group Photo	Location TBC
1300	Lunch Break	
	SESSION 3	
1400	Definitive treatment, postop, reirradiation, oligomets, rare tumors: Where can and should we use SABR in head and neck cancer?	Dr Pierre Blanchard
	Expert panel discussion #1	Moderators: Dr Tomas Kron &
1440	How to assess and prevent side effects with SABR. Are we doing enough?	Dr Shankar Siva (with our 5 International Speakers)
1520	Break	
	SESSION 4	
1550	SABR Beyond Cancer: Treating Cardiac Arrhythmia	Dr Barbara Jereczek-Fossa
1630-1720	Debate: "In the future, advances in SABR will be driven by technology, not biology"	Affirmative: <b>Dr Lauren Henke</b> Negative: <b>Dr Drew Moghanaki</b>
1730 – 1930	Welcome Reception Level 13 Event Space @Peter Mac, 305 Grattan St, Parkville	





## SATURDAY 15<sup>TH</sup> NOVEMBER

TIME	EVENT	SPEAKER
	SESSION 5	
900	Complex Prostate SABR: From High-Risk to Re- Irradiation and Prostate Bed	Dr Barbara Jereczek-Fossa
940	Is SABR a standard of care for prostate oligometastatic disease?	Dr Pierre Blanchard
1020	Break	
	SESSION 6	
1100	How would we do sim-free SABR?	Dr Melissa O'Neil
1140	CT guided adaptive pancreas SABR	Dr Lauren Henke
1220	Expert panel discussion #2 Necessary compromises in SABR	Moderators: Dr Tomas Kron & Dr Shankar Siva (with our 5 International Speakers)
1300	Lunch Break	
	SESSION 7	
1400	Interactive session #2: SABR workflow optimization and implementation	Facilitators: Mr Tom Devereux & Dr Adam Yeo
1500	Impact of SABR on lung cancer screening	Dr Drew Moghanaki
1540	Summary and closing comments	Dr Shankar Siva
1600	Symposium Close	